HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for Presentation at the National Organization for Rare Disorders' Rare Diseases and Orphan Products Breakthrough Summit
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...
Christopher Pullion Us Congress National Organization For Rare Disorders Us Development Biomedical Advanced Research National Institute Of Allergy
Source: prnewswire.com